Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)

Bibliografske podrobnosti
Main Authors:	Charlton-Menys, V, Betteridge, D, Colhoun, H, Fuller, J, France, M, Hitman, G, Livingstone, S, Neil, H, Newman, C, Szarek, M, Demicco, D, Durrington, P
Format:	Journal article
Jezik:	English
Izdano:	2009

Podobne knjige/članki

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Charlton-Menys, V, et al.
Izdano: (2009)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Charlton-Menys, V, et al.
Izdano: (2009)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Colhoun, H, et al.
Izdano: (2009)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
od: Newman, C, et al.
Izdano: (2006)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Newman, C, et al.
Izdano: (2008)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Hitman, G, et al.
Izdano: (2007)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
od: Newman, C, et al.
Izdano: (2005)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
od: Colhoun, H, et al.
Izdano: (2004)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Raikou, M, et al.
Izdano: (2007)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)
od: Betteridge, D, et al.
Izdano: (2009)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
od: Hitman, G, et al.
Izdano: (2005)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
od: DeMicco, D, et al.
Izdano: (2005)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
od: Colhoun, H, et al.
Izdano: (2005)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
od: Neil, H, et al.
Izdano: (2006)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
od: Thomason, M, et al.
Izdano: (2004)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
od: Colhoun, H, et al.
Izdano: (2002)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
od: Raikou, M, et al.
Izdano: (2005)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
od: Charlton-Menys, V, et al.
Izdano: (2009)

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
od: Soedamah-Muthu, S, et al.
Izdano: (2011)

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
od: Colhoun, H, et al.
Izdano: (2011)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
od: Soedamah-Muthu, S, et al.
Izdano: (2003)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
od: Harshal A. Deshmukh, et al.
Izdano: (2012-05-01)

Statines in treatment of patients with diabetes mellitus: niche of atorvastatine
od: S. A. Urazgildeeva
Izdano: (2018-03-01)

Status report of lipid-lowering trials in diabetes.
od: Betteridge, D, et al.
Izdano: (2000)

Role of Ezetimibe in Combination with Statins(Simvastatin and Atorvastatin) in Controlling Dyslipidemia
od: Falah H.Al-Malki, et al.
Izdano: (2017-03-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
od: N. G. Gogolashvili
Izdano: (2015-09-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
od: N. G. Gogolashvili
Izdano: (2015-09-01)

Pleiotropic effects of statins at the present stage of their study (focus on atorvastatin). Part III. Mechanisms of the pleiotropy of statins
od: D. M Aronov
Izdano: (2013-06-01)

Statins and diabetes - Reply
od: Kearney, P, et al.
Izdano: (2008)

Pharmacogenetic Approaches to Enhancing Efficacy and Safety of Statins as Illustrated by the Example of Atorvastatin
od: R. Ye. Kazakov, et al.
Izdano: (2020-03-01)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
od: Masadeh Majed, et al.
Izdano: (2012-05-01)

Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients
od: Saeed Kalantari, et al.
Izdano: (2014-01-01)

Statin-induced myopathy associated with atorvastatin therapy in the elderly patient. Clinical case
od: Natalia A. Cherkasova, et al.
Izdano: (2021-10-01)

Statins and diabetes - Authors' reply
od: Kearney, P, et al.
Izdano: (2008)

STATINS AND THE RISK OF DIABETES MELLITUS
od: O. M. Drapkina
Izdano: (2015-09-01)

STATINS AND THE RISK OF DIABETES MELLITUS
od: O. M. Drapkina
Izdano: (2015-09-01)

Statins and diabetes: focus on pitavastatin
od: Soreiia A. Urazgildeeva
Izdano: (2020-09-01)

FREQUENCY AND CORRELATES OF MYOPATHY IN PATIENTS WITH DIABETES TAKING ATORVASTATIN
od: Kamil Rehman Butt, et al.
Izdano: (2021-04-01)

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes
od: Deedwania, PC, et al.
Izdano: (2016)

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke
od: QianQian Bi, et al.
Izdano: (2022-11-01)